Falconbury Logo
Presented by

Drafting Commercial Contracts for the Pharmaceutical Industry Training Course

A two-day practical and interactive seminar focusing on current contract drafting, negotiating, best practice and related issues within the pharmaceutical, biotech and life sciences sectors.

★★★★★ "All presentations were nicely structured and have provided clear and understandable insights into in... more (48)"

8-9 July 2024
+ 20-21 November 2024 »

from £999

Need help?  Enrol or reserve

Course overview

In such a highly regulated industry and in these turbulent and uncertain times, understanding the key challenges of negotiating and drafting an effective and watertight contract on an international level are complex topics. They can be difficult for even the most well-equipped in-house lawyer and most often it is not the lawyer in the driving seat.

Commercial managers from all areas of the pharmaceutical industry are leading negotiations and drafting and managing key contracts on a daily basis. It is vital that both legal counsel and commercial executives not only have the key skills and tactics to create a win:win scenario but also the knowledge to ensure any agreement is within current laws and regulations. The alternative is the exposure of the organisation to unnecessary risk and costly disputes.

The programme will:

  • Deliver an in-depth examination of intellectual property issues that affect pharmaceutical industry agreements
  • Focus on competition regulations pertinent to pharmaceutical industry agreements
  • Analyse the commercial and legal issues affecting pharmaceutical industry agreements
  • Examine collaboration and licensing agreements

The delivery style
This unique and highly interactive two-day programme looks at all stages of the contracting process and aims to deliver applied training through a balanced blend of practical learning. The presenters will use a mixture of practical exercises and case from the pharmaceutical industry to ensure you leave the seminar with the knowledge and skills to perfect all stages of the contracting process.

This training course is part of our Commercial Contracts Training Course collection which has been designed for the in-house lawyer.

Who should attend?

Personnel from R&D, clinical, regulatory, commercial, sales and marketing, manufacturing, distribution and purchasing functions, including:
  • In-house counsel
  • Commercial and contract managers
  • Business development managers
  • Purchasing and procurement
  • Heads of legal departments
  • Legal advisers
  • Patent, IP, trade marks or licensing counsel

The key objectives

By attending this seminar, you will:

  • Update your practical skills when drafting effective licensing and collaboration agreements
  • Explore the current issues relating to IP including the Unitary Patent and Unified Patent Court 
  • Understand the key intellectual property issues affecting pharmaceutical industry agreements
  • Find out about the implications of SPCs for pharmaceutical industry agreements
  • Learn how to draft contracts to avoid anti-trust infringement
  • Familiarise yourself with the key commercial and legal issues that affect pharmaceutical industry agreements
  • Gain knowledge of the key issues in clinical trial agreements, contract manufacturing agreements and co-promotion, co-marketing and distribution agreements, and material transfer agreements
  • Get to grips with competition law relevant to doing deals in the pharmaceutical industry and the tactics

Enrol or reserve

The Drafting Commercial Contracts for the Pharmaceutical Industry course will cover:

Understanding licensing and collaboration agreements

  • Precontractual documents and the role of the term sheet
  • Scope of the licence
  • The interplay of key commercial terms, including:
    • governance and dispute resolution
    • performance obligations and termination rights
    • financial terms
  • Boilerplate clauses, including law and jurisdiction

Intellectual property terms in licensing and collaboration agreements

  • Ownership of internally and externally generated IP
  • Joint ownership issues
  • Outsourcing issues
  • Improvements and grant backs
  • Sample clauses

The Unitary Patent and the Unified Patent Court

  • Latest developments
  • Implications for the pharmaceutical industry

Third-party IP rights – freedom-to-operate searches and implications for pharmaceutical industry agreements

  • Evaluating your freedom to operate
  • Different approaches to infringement in Europe
  • Assessment of injunction risk
  • Mitigating risk and pre-launch patent strategies more generally
  • Strategies for obtaining freedom to operate including via licensing
  • Freedom-to-operate warranties and indemnities
  • Payments and royalty stacking
  • Enforcement against infringers
  • No-challenge clauses
  • Benefits of recording your licence

Supplementary protection certificates (SPCs) – securing the full commercial potential of your product

  • What are SPCs?
  • What are the implications for pharmaceutical industry agreements?
  • The duration of the SPC
  • What does the SPC cover?
  • Combination products
  • Basic patents and basic follow-on SPCs
  • Leveraging the full commercial value of your property

Understanding and drafting R&D agreements

  • The scope and purpose of R&D agreements
  • Key terms and conditions
  • Limitations of experimental use defence to patent infringement
  • The 'Euro Bolar' defence: Article 10(6) Directive 2001/83/EC explained
  • The varying scope of the 'Euro Bolar' defence across the EU and how it has been implemented in UK law

Medicines regulations using regulatory processes to define contractual obligations

  • An introduction to regulatory law
  • Brief contrast of differing regulatory regimes: medicines/ devices
  • Milestones in approving medicines
  • Using regulatory processes and milestones in defining contractual obligations
  • Common pitfalls and hot spots

Key issues in clinical trials and related agreements

  • Introduction to clinical trials
  • Outline of principal EU and UK legislation
  • Structuring clinical trial agreements
  • Engaging CROs
  • Key agreement terms and obligations
  • Liability and indemnities

Key issues in contract manufacturing agreements

  • The importance of the GMP audit
  • Issues with technology transfer
  • Apportionment of risk and reward
  • Secondary sources of supply
  • Building a supply chain
  • Other key issues

Key issues in co-promotion, co-marketing and distribution agreements

  • Introduction to the agreements
  • Scoping the deal
  • Preparing for contingencies and termination
  • Key characteristics of the distribution relationship
  • Key terms – scope of rights and responsibilities, restrictions, minimum purchase requirements, territory

Key issues in material transfer agreements

  • The purpose of the agreement
  • The scope of the agreement
  • Key terms and conditions
  • Key issues to be aware of

Introduction to relevant EU competition law rules

  • Article 101 TFEU and 102 TFEU: restrictive agreements and practices and abuse of dominance in pharmaceutical markets
  • The December 2010 Horizontal Cooperation Guidelines
  • The Jan 2011 R&D Block Exemption – strategy for early joint research
  • The Technology Transfer Block Exemption – dos and don’ts for licensing in and out
  • The Vertical Agreements Block Exemption and Vertical Restraints Guidelines – designing distribution models in the EU
  • Specialisation Agreements Block Exemption
  • Implications of Brexit

Practical workshop: Current competition law issues

  • Reduced and exclusive distribution agreements
  • Licensing in and out
    • The new technology transfer exemption
  • Quota schemes and other devices for protecting domestic needs
  • Discount schemes for dominant companies

Enrol or reserve

Niels Ersbøll
Arnold & Porter LLP

Niels Ersbøll, Partner, Arnold & Porter LLP, advises clients on EU competition law in relation to cartels and restrictive practices, merger control, abuse of dominance and State aid. He is currently involved in several pending EU cartel investigations. He advises on merger control investigations by the European Commission and competition authorities worldwide for clients such as General Electric, Boston Scientific, Pfizer, and Sanyo. Where investigations (mergers or cartels) are run by several authorities in parallel, he assists with overall strategy and coordination. Niels also has significant experience helping clients with designing and implementing compliance measures and conducting internal investigations and audits.

More details

Stephen Reese
Clifford Chance LLP

Stephen Reese is a partner at Clifford Chance and advises clients on both contentious and non-contentious intellectual property matters including patents, trade marks, trade secrets and copyright. Stephen represents and advises a broad range of clients in relation to the protection, exploitation and enforcement of their intellectual property rights. With significant experience representing clients within the life sciences and technology fields, Stephen has acted on some of the most significant licensing transactions in the life sciences industry. Since 2010, Stephen has been listed as one of IAM’s Top 250 Patent Licensing specialists.

More details

Mario Subramaniam
Bird & Bird

Mario Subramaniam is a Legal Director in the Life Sciences Transactions team at Pinsent Masons. As a former research scientist, he has a passion for the life sciences and has expertise in advising clients on intellectual property, commercial and regulatory aspects of the pharma, biotech, medtech and digital health sectors. He has advised on agreements that span the product life cycle, including strategic licensing and research collaboration arrangements, clinical trials, manufacturing, supply and distribution agreements. Having previously been in-house counsel at a number of prominent life science companies, Mario has a deep understanding of clients’ needs in this sector and is renowned for his clear and practical advice.

More details

Ben Thomas
Simmons & Simmons LLP

Ben Thomas is a Managing Associate at Simmons & Simmons. He has experience of working across a range of contentious and non-contentious intellectual property matters, with a focus on patent and supplementary protection certificate litigation. Assisted by his strong technical background in biochemistry, Ben has a particular interest in the life sciences sector. He has acted for clients in a wide variety of industries, including pharmaceuticals, vaccines and medical devices, TMT and consumer goods (e.g. laundry detergents, vaping devices). He has acted for clients in disputes before the English Patents Court, the UK and European Union Intellectual Property Offices, and the General Court and Court of Justice of the European Union.

More details

James Agnew
Simmons & Simmons LLP

James Agnew is a supervising associate at Simmons & Simmons. He has worked on a range of contentious and non-contentious intellectual property matters including commercial licensing, collaboration agreements, software protection, settlement proceedings and the intellectual property aspects of corporate transactions, financings and commercial arrangements. James also advises on life sciences regulatory issues including the promotion of medicines and devices and interactions with healthcare professionals. He has experience in a wide range of industries, including life sciences, TMT, finance, Fintech, energy and defence, with a focus on transactions involving intellectual property.

More details

Tom Carver
McCarthy Denning

Tom Carver is a partner at White & Black Legal. He has broad experience in patent litigation (infringement and validity) in pharmaceuticals, medical and mechanical devices and electronics, including advice concerning threats provisions. Tom co-ordinates and manages litigation in multiple jurisdictions, and has particular expertise in biotech patent litigation. Tom has a degree in genetics and worked on the first patent case in the UK relating to genetically modified organisms, Monsanto v Cargill, and the first patent case in the UK on DNA sequences, Eli Lilly v Human Genome Sciences. He has been involved in some of the most significant patent cases in the UK in recent years. Tom lived in China for three years, where he managed intellectual property enforcement for Western clients, including Dyson. His experience includes patent (design, utility and invention), trade secret, trade mark and copyright litigation against companies in provinces across China in sectors including capital and consumer goods, cosmetics and medical devices. He also has experience of non-judicial IPR enforcement in China at trade fairs, online and by Customs seizures.

More details

Fred Nicolle
Simmons & Simmons

Fred Nicolle is a UK and European qualified patent attorney (CPA, EPA) at Simmons & Simmons. He has over 15 years experience specialising in patent prosecution and contentious matters for the life sciences sector. He has particular expertise in pharmaceuticals, medical devices, consumer health products, cosmetics, foods and health supplements. He graduated from the University of Cambridge with a Master of Natural Sciences degree with a final year research project in synthetic organic chemistry.

Fred has extensive experience of contentious patent proceedings in opposition at the European Patent Office and in national litigation, having defended patents for numerous commercially important products. Notable examples include the defence of patents for Noctiva™ (desmopressin acetate nasal spray), Bendeka® (bendamustine HCl injection), Revlimid® (lenalidomide), Xeplion®/Invega Sustenna® (paliperidone palmitate), wound dressings, and contact lenses.

Fred is featured in The Legal 500 and IAM Patent 1000 as a recommended patent attorney.

More details

Alex Denoon
Bristows LLP

Alex Denoon is head of the regulatory team at Bristows, primarily advising life sciences clients. He has more than 20 years’ experience advising clients in the sector. In addition to his LLB, Alex has a BSc in Human Genetics. Alex spent more than five years in-house, including as GC and Company Secretary of Biotech Australia. He works with clients to devise and implement regulatory strategies throughout the product life cycle of pharmaceuticals and medical devices, and has advised clients in relation to more challenging issues including: genomics, cell therapies, tissue and cells requirements, borderline products, combination products, 3D printing, healthcare apps and remote diagnostics, and has been involved in the development of a number of regulatory frameworks and guidelines.

In addition to a range of contentious (judicial review) and advisory matters, he has a breadth of international experience in structuring, negotiating and drafting commercial agreements. Alex is widely published and speaks regularly at conferences.

More details

Xisca Borras

Xisca is a dual-qualified lawyer in England & Wales and Spain who specialises in all aspects of EU and UK regulatory law in the biopharmaceutical sector.

Previously she was an in-house lawyer at a leading innovative biopharmaceutical company, where she provided regulatory law support to all business units and functions at EU and global level, gaining excellent knowledge of the pharmaceutical industry enabling her to bring a strong business approach to her legal advice. Prior to that, she was an associate in the IP litigation team at a magic circle law firm in Barcelona for almost 10 years.

Xisca advises on a broad range of regulatory law topics including: regulatory strategies for bringing products to market, product lifecycle management, regulatory exclusivities, clinical trials and non-interventional trials, including the implementation of the Clinical Trial Regulation, orphan medicinal products, obligations and rewards in relation to paediatric research including agreeing and modifying PIPs, waivers and deferrals and compliance with agreed PIPs, and parallel trade of medicines.

She has broad experience in manufacturing and distribution issues, including supply management policies, product shortages and recalls, and compliance with GMP, GDP and labelling requirements. She has supported GCP and GMP inspections, both at national and EU level.

Xisca also advises on the consequences of Brexit, including changes required to ensure business continuity further to the UK’s withdrawal from the EU.

More details

Ewan Townsend
Arnold & Porter

Ewan Townsend is Counsel in Arnold & Porter’s London office and assists clients in the life sciences sector on regulatory and commercial matters. He has experience with a broad range of regulatory issues that arise throughout the medicinal product and medical device life cycle, including research and development, clinical trials, marketing authorisations, manufacturing, distribution, advertising, pricing and reimbursement. Ewan’s work also includes drafting and negotiating commercial agreements for his life sciences clients, such as licence agreements, manufacturing, distribution and supply agreements, clinical trial agreements and service agreements, and advising on the intellectual property and regulatory issues that arise in the context of those transactions.

More details

Jonathan Dack
Arnold and Porter

Jonathan Dack is a member of the Life Sciences group, advising on a wide range of commercial transactions involving intellectual property, technology and data. With over ten years working in law firms and pharmaceutical companies, his experience includes drafting patent licenses and research collaboration agreements, supply and distribution agreements, clinical trial agreements, and advising on IP commercialization strategy. Jonathan also represents clients in private company M&A (both domestic and cross-border) and manages integration exercises that involve complex IP and technology issues. Jonathan holds an MSc in Regenerative Medicine alongside his legal qualifications. He acts as a Non-Executive Director and Trustee for the UK Stem Cell Foundation.

More details

NEW higher discounts for multiple bookings - bring your colleagues to make your training budget go further:

  • 30% off the 2nd delegate*
  • 40% off the 3rd delegate*
  • 50% off the 4th delegate*

Please contact us for pricing if you are interested in booking 5 or more delegates

8-9 July 2024

Rembrandt Hotel

09:00-17:00 UK (London)
Course code 13782
Optional £280/€395/$450 per night

  • GBP 1,199 1,399
  • EUR 1,729 2,009
  • USD 1,977 2,289

Until 03 Jun

  • 2 days classroom-based training
  • Optional accommodation - 2 nights including breakfast, checking in the day before the course
  • Meet presenters and fellow attendees in person
  • Lunch and refreshments provided
  • Download documentation and certification of completion
  • Fair transfer and cancellation policy

View basket 

Not ready to book yet?

for 7 days, no obligation

20-21 November 2024

Live online

09:30-17:30 UK (London) (UTC+00)
10:30-18:30 Paris (UTC+01)
04:30-12:30 New York (UTC-05)
Course code 14039

  • GBP 999 1,199
  • EUR 1,439 1,719
  • USD 1,647 1,959

Until 16 Oct

View basket 

Not ready to book yet?

for 7 days, no obligation

* Early booking discounts may not be combined with other discounts or offers. As such, the discounts for 2nd/3rd/4th delegates are based on the full price.

Reviews of IPI's Drafting Commercial Contracts for the Pharmaceutical Industry training course

All presentations were nicely structured and have provided clear and understandable insights into individual issues in the pharmaceutical industry. Very pleasant environment and very high quality speakers.

Jul 10 2023

Patricia Baratova
Legal Counsel , Sun Pharmaceutical Industries (Europe) B.V.

Nov 23 2022

Excellent webinar, I would (and did) highly recommend it. Large variety of subjects with much useful insights and information. The different speakers make it more dynamic and they were all very open to discussion and/or taking questions.

Juliette Gordeau
Legal Counsel, TRB Chemedica International S.A.

Nov 24 2021

I found the webinar very informative and helpful. The speakers were very clear and practice-oriented.

Maria João Rodrigues
Legal Counsel, BIAL - Portela & Companhia SA

Nov 24 2021

Overall it was very good

Cristina Bertulli
Director of Business Development and Operations , Exactmer Ltd

Nov 19 2019

This course was brilliant and covered all the key points. The speakers were highly knowledgeable and had practical insights and fresh perspectives on drafting issues and implications. Having multiple speakers allowed for a fresh and dynamic course, and increased the amount of information absorbed.

James Langston
Contracts Manager, AstraZeneca

Nov 19 2019

Good overview of content, great organisation.

Amish Unka
Legal Counsel, Morningside Healthcare Limited

Jun 5 2019

High quality content and course materials. Professional presentation within a relaxed learning environment. Fantastic speakers who were happy to answer questions during their talks and the breaks.

Grace Hamlett
Legal Counsel, Mereo BioPharma

Nov 20 2018

Insightful teachers, great take-home material, stupendous learning environment.

Luis Briseno Roa
Associate Director, Alexion R&D France

Nov 20 2018

A fantastic program and great speakers/participants.

Mia Rensch-Jacobsen
Business Operations Manager, Roche Innovation Center Copenhagen

Jun 6 2018

All speakers are excellent and experts in their fields – I really enjoyed listening to them. The course is very extensive covering a wide variety of topics.

Avadhanula Yagna Praveen Kumar
Head of Intellectual Property Management, Pharmaniaga Berhad

Nov 20 2018

Very useful course for my future career.

Christopher France
Business Development Associate, GSK Vaccines Srl

Nov 20 2018

Great and useful course.

Taisier Adil
Legal Counsel, Xendo Holding B.V. – A ProPharma Group Company

Jun 6 2018

Good topics and speakers.

Wan Intan Idura Wan Ismail

Jun 6 2018

Excellent and immediately useful.

Dan Hudson
Manager, GSK Vaccines SRL

Jun 6 2018

I particularly liked the quality of the speakers and the various workshops.

Zian Bertrand
In-House Counsel , ERYTECH PHARMA

Nov 20 2017

I think that overall the course material was comprehensive and touched on a lot of different topics. I would recommend this course.

Angele Azzopardi
In House Legal Counsel , Starpharma Malta

Nov 20 2017

Very good course and good presentations/topics.

Ilaria Pastorello
Manager Vaccines Business Development, GSK Biologicals SA

Nov 20 2017

The content was very good and I appreciated the booklet provided. I found ... the speakers very engaging and everything was well organised and well presented.

Leah Baker
Pharmacovigilance Scientist, Norgine Ltd

Nov 20 2017

I found the course very practical and engaging

Tania Damianova
Company Lawyer, UCB S.A.

Jun 7 2017

The content is excellent. The speakers are highly qualified and talented in terms of lecturing.

Moataz Mahmoud
Legal & Compliance Advisor, EBN Sina Medical Establishment

Nov 20 2017

Very informative, very knowledgeable speakers, content good.

Luciana Schwambach
Contract Manufacturing Business Development Director, Xellia Pharmaceuticals ApS

Nov 20 2017

Very knowledgeable experts.

Olivia Chalwin
Major Contracts Manager, University of Southampton

Jun 7 2017

Very good, good alignment with professional practice.

Erik Popping
Corporate & Legal Counsel, Intravacc

Nov 23 2016

Great material and speakers

Paraskevi Sakallaridi
Lawyer, ELPEN Pharmaceutical Co. Inc.

Nov 23 2016

Good overall impression. Certain topics remained at introductory level without going into depth

Lina Yaneva
Legal Counsel, Mylan SAS

Jun 8 2016

The course was well organised. Unfortunately patent issues were skimmed over

Jeremy Whitman
Legal Department, Sterling S.p.A.

Nov 23 2016

Very interesting topics

Khady Seck
Mylan S.A.S.

Nov 18 2015

Very well organised, really enjoyed the higher energy speakers as I find it difficult to sit through three days if the speakers are low energy

Darragh O'Dea
Legal Counsel, BioMarin Pharmaceutical

Nov 18 2015

The course was good. I would suggest more practical examples.

Elda Selfo
Site Contract Specialist , INC Research

Nov 18 2015

Overall good. The seminar room with no windows and fresh air was the only negative.

Kristina Anna Reitmeier
European PharmInvent Services, s.r.o.

Jun 2 2015

Very professional. Some of the speaker were too fast, but all of them very friendly and kind.

Roberto Aldovini
Legal Counsel, APR Applied Pharma Research s.a

Jun 2 2015

Enough but not very deep

Eva Rosal Negre
Legal Advisor , Laboratories Hipra, S.A

Jun 2 2015

Organisations are paying a considerable amount for their employees to attend this course and the speakers should therefore deliver better presentations. The good speakers were engaging, interested in feedback and seemed to care. Given the professional level of the speakers the lack of professionalism in the way that they presented their subject in the time available was surprising.

Rachel Simpson
Contracts Manager, University of Dundee

Nov 18 2015

Days 1-2 were very detailed, although some presenters did not encourage interaction

Neil Thompson
Supply Chain Manager, Suir Pharma Ireland

Nov 19 2014

Generally high quality speakers. Good all-round refresher and networking opportunity.

Nick Plummer
Senior Director, EU Legal Services , Patheon UK Ltd

Nov 19 2014

The content was really interesting and useful, was communicated effectively and all the presenters were good. The negotiation part was great!

Eleni Pentafragka

Nov 19 2014

Very helpful for practising in-house lawyers courses. The negotiation strategies workshop should have been adapted to lawyers.

Maria Ganeva
Contracts Manager, Genzyme

Nov 19 2014

Speakers were fine and knew the subject well but some presentations were superficial

Maria Teresa Vazquez Calo
Lawyer, Assesora estudio jurídico y tributario S.L.P

Nov 19 2014

More case studies would be better

Jan Smidrkal
Tech Transfer Manager, Institute of Chemical Technology Prague

Jun 3 2014

Very good course, but many details covered in a short time.

Christopher Lambert
Chief Legal Officer, Fertin Pharma A/S

Nov 18 2013

The course was excellent, very useful and well organized.

Borislav Dakic
Director of Legal Department, Hemofarm AD

Nov 18 2013

Really excellent including Susan Sungleton

Patricia Hoyle
Global Head Intellectual Property, Evolva Holding SA

Jun 5 2013

Speakers were well prepared and had good presentation skills. I enjoyed the course.

Dragan Lutz

Nov 18 2013

Content was useful, but I would recommend a bit more focus on generics as well. All speakers were competent and presented well.

Milica Milekic
Senior Legal Counsel, HEMOFARM AD

Jun 5 2013

Lots of content, some very good presentations and speakers.

Rebecca Flory
Solicitor, Edinburgh Research & Innovation Ltd

Nov 12 2012

Very relevant and useful to the topic of drafting commercial agreements in the pharma industry

Asif Altaf
Allergan Ltd

Nov 12 2012

Very helpful and detailed material, good coverage of all pharma legal issues considering time available.

Roberta Comerro
Ginsana SA

Nov 12 2012

Given the various topics being covered in a span of 3 days I think the speaker couldn't have done better

Sangeeta Shah
Mercury Pharma

United Kingdom

  • Torbay Pharmaceuticals
  • 3M Health Care Ltd
  • Accord Healthcare
  • Adaptimmune Limited
  • Adaptimmune Ltd
  • Allergan Ltd
  • Almac Group
  • Almac Group Limited
  • Anderson Law LLP
  • Apotex
  • Ark Therapeutics Ltd
  • Arnold & Porter (UK) LLP
  • Artios Pharma Limited
  • Astellas
  • Astellas Pharma Europe Ltd
  • AstraZeneca
  • AstraZeneca (Macclesfield)
  • Autolus
  • Bard Pharmaceuticals
  • Biofocus DPI
  • Boehringer
  • Boehringer Ingelheim Limited
  • Bristol-Myers Squibb Pharmaceuticals Limited
  • Bristows LLP
  • Britannia Pharmaceuticals Ltd
  • British American Tobacco
  • Burges Salmon
  • Cancer Research UK
  • Centroflora CMS
  • Chemidex Pharma Limited
  • Clearly Gottlieb Steen & Hamilton
  • Clinuvel UK Ltd
  • CMC Biopharmaceuticals
  • Coalition for Epidemic Preparedness Innovations
  • Consilient Health
  • Corin Limited
  • Covington & Burling
  • Covington & Burling LLP
  • Dechra Pharmaceuticals plc
  • Dexcel Pharma Ltd
  • Dickinson Dees LLP
  • Dishman Europe Ltd
  • Dr Reddys
  • Edinburgh Research & Innovation
  • Edinburgh Research & Innovation Ltd
  • Emergent Product Development UK Ltd
  • EUSA Pharma (UK) Ltd
  • Evotec UK LTd
  • Evox Therapeutics
  • Exactmer Ltd
  • F2G Ltd
  • Ferring Pharmaceuticals Ltd
  • GE Healthcare Limited
  • Genzyme Therapeutics Ltd
  • Gilead Sciences
  • GlaxoSmithKline
  • GlaxoSmithKline Services Unlimited
  • Glenmark Pharmaceuticals Europe R&F Ltd
  • GW Pharmaceuticals
  • IDIS Ltd
  • INC Research
  • Indivior PharmaceuticalUK Ltd.
  • Juniper Pharma Services Ltd
  • Kent Pharmaceuticals Ltd
  • Lonza Biologics
  • Merck Sharp and Dohme Limited
  • Mercury Pharma
  • Mereo BioPharma
  • Mitsubishi Tanabe Pharma Europe Ltd
  • Morningside Healthcare Limited
  • Muckle LLP
  • Mundipharma International Limited
  • Mylan
  • Mylan Inc
  • Napp
  • Napp Pharmaceutical Holdings Ltd
  • Napp Pharmaceuticals Ltd
  • Nicoventures Limited
  • Norbrook Laboratories
  • Norgine Ltd
  • Nottingham University Hospitals NHS Trust
  • Nova Laboratories Ltd
  • Novo Nordisk
  • Otsuka Pharmaceutical Europe Ltd
  • Oxagen Ltd
  • Oxford Biomedica
  • Oxford BioTherapeutics
  • Patheon UK Ltd
  • Penn Pharma
  • Porton BioPharma
  • Porton Biopharma Ltd
  • QA Ltd
  • Randox Laboratories Limited
  • Roche Products Ltd
  • Rosemont Pharma Ltd
  • Servier Labs Ltd
  • Seven Seas Ltd
  • Sigma Aldrich Co Ltd
  • Sosei Heptares
  • Synth-Isis Ltd
  • Takeda
  • Teva UK Ltd
  • The University of Edinburgh
  • Tillotts Pharma AG
  • UBC late stage(UK)Ltd
  • UCB Pharma
  • University of Dundee
  • University of Southampton
  • Vectura Ltd
  • Vertex Pharmaceuticals (Europe) Ltd
  • Vitabiotics Ltd
  • Volition Diagnostics UK Ltd
  • VWV
  • Warner Chilcott (UK) Ltd
  • West Pharmaceuticals Services Ltd


  • Acino International
  • Actelion Pharmaceutical Ltd
  • APR Applied Pharma Research s.a
  • Bachem AG
  • Biogen Idec
  • CHEMO SA, Lugano Branch
  • CimArk SA
  • Clinuvel AG
  • Debiopharm International SA
  • DNDi
  • Drugs for Neglected Diseases initiative (DNDi)
  • Evolva Holding SA
  • F Hoffmann La Roche AG
  • F. Hoffmann-La Roche Ltd
  • Factor
  • Ferring International Center S.A.
  • Ginsana SA
  • Helsinn Chemicals SA
  • Helsinn Healthcare S.A.
  • Helsinn Healthcare SA
  • Linnea
  • Merck Serono SA
  • MMV Medicines for Malaria Venture
  • Novartis Consumer health
  • Novartis Consumer Health S.A.
  • Novartis Pharma AG
  • Octapharma AG
  • OM Pharma SA
  • Siegfried AG
  • Siegfried Ltd
  • Stragen Pharma SA
  • Takeda Pharmaceuticals International GmbH
  • The Medicines Patent Pool Foundation
  • tillotts pharma AG
  • TRB Chemedica International S.A.
  • TRB Chemedica SA
  • Vifor (International) Ltd.
  • Vifor Pharma Ltd.


  • 3M Deutschland GmbH
  • Biontech AG
  • BioNTech Business Services GmbH
  • BioNTech SE
  • Biotest AG
  • Boehringer Ingelheim
  • Boehringer Ingelheim GmbH
  • Boehringer Ingelheim Pharma GmbH & Co. KG
  • Dr Kade Pharmazeutische Fabrik GmbH
  • Fresenius Medical Care
  • Fresenius SE & Co. KGaA
  • GPC Biotech AG
  • Graf von Westphalen
  • Grünenthal GmbH
  • Grünenthal Pharma GmbH & Co KG
  • Grünenthal Pharma GmbH & Co.KG
  • Intendis GmbH
  • Jerini AG
  • Morphosys AG
  • Mundipharma GmbH
  • Teva
  • Umicore AG & Co. KG
  • Vetter Pharma-Fertigung GmbH & Co KG
  • Wilex AG


  • ALK-Abelló AS
  • Ascendis Pharma A/S
  • Chr. Hansen Holding A/S
  • Dako Denmark AS
  • Ferring Pharmaceuticals A/S
  • Fertin Pharma
  • Fertin Pharma A/S
  • Fertin Pharma AS
  • Genmab A/S
  • Genmab AS
  • Holst, Law Firm
  • LEO Pharma
  • Leo Pharma A S
  • LEO Pharma A/S
  • Leo Pharma AS
  • Novo Nordisk A/S
  • NsGene AS
  • Roche Innovation Center Copenhagen
  • Statens Serum Institut
  • Tech Trans Unit
  • Thrombologic ApS
  • Veloxis Pharmaceuticals AS
  • Xellia Pharmaceuticals
  • Xellia Pharmaceuticals ApS


  • Alexion R&D France
  • Aptargroup UK Holdings Limited
  • CEPI (Coalition for Epidemic Preparedness Innovations)
  • ERYtech Pharma
  • Flamel Technologies
  • Laboratoires Bouchara Recordati
  • LFB
  • Mylan
  • Mylan S.A.S.
  • Mylan SAS
  • none
  • Nordic Pharma SAS
  • Orphalan
  • Sanofi Aventis Group
  • Sanofi Aventis Groupe
  • Sanofi Aventis Recherche et Developpement
  • Sanofi-Aventis
  • Sanofi-Aventis Groupe
  • Takeda


  • Accord Healthcare SLU
  • Almirall, SA
  • Assesora estudio jurídico y tributario S.L.P
  • AstraZeneca Farmaceutica Spain, ss
  • Bioiberica SA
  • Chemo España
  • CHEMO Group
  • Cloverty
  • Corporación Medichem, SL
  • Isdin
  • J Uriach y Compania SA
  • Laboratories Hipra, S.A
  • Laboratorios Almirall SA
  • Laboratorios Liconsa, SA
  • Mabxience Holding
  • Medichem
  • Moehs Iberica, Sl


  • Ablynx
  • Ajino Moto - Omnichem
  • Ajinomoto Omnichem\_Omnichem Division
  • Celyad SA
  • GlaxoSmithKline
  • GlaxoSmithKline Biologicals SA
  • GSK
  • GSK Biologicals SA
  • Lonza Braine
  • UCB Biopharma SPRL
  • UCB Pharma
  • UCB Pharma SA
  • UCB S.A.
  • UCB SA
  • VIB
  • VIB vzw


  • Astellas Pharma Europe B.V.
  • AMT BV
  • Crucell Holland BV
  • DSM Sinochem Pharmaceuticals Netherlands B.V
  • Friesland Consumer Products
  • Genzyme
  • Intravacc
  • Kite Pharma
  • Mimetas B.V.
  • PharmaMatch BV
  • Sandoz
  • Sanquin
  • Sun Pharmaceutical Industries (Europe) B.V.
  • Sun Pharmaceutical Industries Europe BV
  • Synthon BV
  • University Medical Center Utrecht
  • Xendo Holding B.V. – A ProPharma Group Company


  • Angelini Farmaceutica
  • Aptuit (Verona) Srl
  • Covidien Italia SpA
  • Eli Lilly Italia Spa
  • Fondazione Centro San Raffaele Del Monte Tabor
  • GlaxoSmithKline
  • GSK Vaccines SRL
  • Molmed SpA
  • Recordati S.p.A
  • Roche SpA
  • Sterling S.p.A.
  • Studio Legale Lupi & Associati


  • AOP Orphan Pharma
  • Boehringer Ingelheim RCV GmbH & Co KG
  • Boehringer Ingelheim RCV GmbH&Co KG
  • Boehringer Ingelheim RCVGmbH & Co KG
  • Boehringer-Ingelheim RCV GmbH & Co KG
  • Ebewe Pharma
  • Eli Lilly Regional Operations
  • Hookipa Biotech GmbH
  • Intercell AG
  • Pharmaselect international Beteiligungs GmbH.
  • Treibacher Industrie AG


  • Abbott Ireland Ltd
  • Amarin
  • BioMarin Pharmaceutical
  • Elan Pharma International Ltd
  • Horizon Therapeutics plc
  • Jazz Pharma
  • Jazz Pharmaceuticals
  • Pfizer Ireland Pharmaceuticals
  • Suir Pharma Ireland


  • ELPEN Pharmaceutical Co. Inc.
  • ELPEN S.A.
  • Genesis Pharma SA
  • Pharmathen SA
  • PharOS - Pharmaceutical Oriented Services
  • Scorinis Law Offices


  • BIAL
  • BIAL - Portela & Companhia SA
  • Bluepharma Industria Farmaceutica SA

United States of America

  • Abbott Laboratories
  • Emergent BioSolutions
  • Grunenthal Latin America Inc.
  • Savara Inc.
  • SMC Ltd

Czech Republic

  • AstraZeneca Czech Republic sro
  • European PharmInvent Services, s.r.o.
  • Institute of Chemical Technology Prague
  • SOTIO a.s.


  • Abbott Products
  • Ispen Pharma
  • Novartis Pharma LLC


  • AstraZeneca
  • Astrazeneca Rod Ab
  • PCG Clinical Services
  • Recipharm AB (publ)


  • Pharmaq AS
  • Pronova Biopharma AS
  • Pronova BioPharma Norge AS


  • Kancelaria Radcy Prawnego
  • Polpharma Trade Office
  • Zaklady Farmaceutyczne Polpharma SA


  • Acino Ukraine LLC, a company of Acino Group, Switzerland
  • Arterium Corporation
  • Farmak Joint Stock Company


  • Xellia d.o.o (Xellia Ltd)


  • Orion Corporation
  • Orion Corporation Orion Pharma

Korea, Republic Of

  • Celltrion Inc.
  • Samsung Bioepis


  • JSC Grindeks
  • Julija Kolomijceva


  • Roche Romania SRL
  • TEVA Pharmaceuticals


  • Hemofarm AD
  • Quintiles doo Beograd


  • K2 Events
  • MN Pharmaceuticals


  • Patrys Limited




  • Actavis EAD


  • Transition Therapeutics


  • GrÜnenthal Colombiana


  • Medochemie Ltd


  • Egis Pharmaceuticals PLC.


  • Hikma Pharmaceuticals


  • Menarini Int. Operations Luxembourg SA




  • Starpharma Malta


  • Novartis Pharma Maroc SA


  • EBN Sina Medical Establishment

Saudi Arabia

  • LFSH


  • LEK Pharmaceuticals dd

United Arab Emirates

  • Gulf Pharmaceutical Industries (Julphar)

Enrol or reserve

Run Drafting Commercial Contracts for the Pharmaceutical Industry Classroom/Live online for your team

3 days

Typical duration

Pricing from:

  • GBP 1,200
  • Per attendee, based on 10 attendees
  • Course tailored to your requirements
  • At your choice of location, or online


We can customise this course to your requirements and deliver it on an in-house basis for any number of your staff or colleagues.

Contact our in-house training experts Aleksandra Beer and Yesim Nurko to discuss your requirements:

Multiple colleagues? See above for details of our discounts for 2, 3, or 4 delegates. For more, talk to one of our training experts to discuss how to:

Run this course conveniently and cost-effectively in-house for your staff and colleagues

Aleksandra Beer

Aleksandra BEER
Training expert

Yesim Nurko

Training expert

+44 (0)20 7749 4749